Eli Lilly (NYSE:LLY) has filed a lawsuit over a U.S. health agency's alleged attempts to block its model for offering rebates for drugs supplied under the government's 340B Program, days after its rival Johnson & Johnson (NYSE:JNJ) filed a similar lawsuit.

Eli Lilly said on Thursday it sued the federal Health Resources and Services Administration (HRSA) over allegedly blocking the company's plan to change the way it offers drug discounts to hospitals. The case centers on the federal 340B program,

Despite rebukes by two federal circuit courts, an HHS sub-agency continues to overstep its authority when administering a drug-discount program.

The company filed a lawsuit asking for a federal court’s permission to change when it gives lucrative drug discounts to hospitals.

Johnson & Johnson files suit against HHS over 340B program, proposing hospitals pay full price upfront for drugs and receive rebates later. Read more here.